Soft chewy confection comprising hmo
US-2024000098-A1 · Jan 4, 2024 · US
Disialyllacto-N-tetraose (DSLNT) or variants, isomers, analogs and derivatives thereof to prevent or inhibit bowel disease
US9675649B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9675649-B2 |
| Application number | US-201213983624-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 3, 2012 |
| Priority date | Feb 4, 2011 |
| Publication date | Jun 13, 2017 |
| Grant date | Jun 13, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides formulations comprising isolated Disialyllacto-N-tetraose (DSLNT) or variants, isomers, analogs and derivatives thereof.
First claim
Opening claim text (preview).
What is claimed is: 1. An infant formula or baby food comprising a formulation that is substantially free of non-disialyllacto-N-tetraose (DSLNT) oligosaccharides, which comprises a pharmaceutically acceptable carrier and an isolated compound selected from the group consisting of α-Neu5Ac-(2→3)-α-Gal-(1→3)-[α-Neu5Ac-(2→6)]-β-GlcNAc-(1→3)-β-Gal-(1→4)-Glc, α-Neu5Ac-(2→3)-β-Gal-(1→3)-[α-Neu5Ac-(2→6)]-α-GlcNAc-(1→3)-β-Gal-(1→4)-Glc, α-Neu5Ac-(2→3)-β-Gal-(1→3)-[α-Neu5Ac-(2→6)]-β-GlcNAc-(1→3)-β-Gal-(1→4)-Glc, β-Neu5Ac-(2→3)-β-Gal-(1→3)-[α-Neu5Ac-(2→6)]-β-GlcNAc-(1→3)-β-Gal-(1→4)-Glc, and α-Neu5Ac-(2→3)-β-Gal-(1→3)-[β-Neu5Ac-(2→6)]-β-GlcNAc-(1→3)-β-Gal-(1→4)-Glc, wherein the formulation comprises at least 800 μM or greater of the compound. 2. The infant formula or baby food of claim 1 , which is a liquid, a gel, or a solid. 3. The infant formula or baby food of claim 1 , wherein the formulation additionally comprises a probiotic. 4. The infant formula or baby food of claim 3 , wherein the probiotic comprises bacterial species from the genera Bifidobacteria and/or Lactobacilli. 5. The infant formula of claim 1 further comprising a vitamin and/or mineral.
Assignees
Inventors
Classifications
Drugs for disorders of the alimentary tract or the digestive system · CPC title
Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor · CPC title
- A61K31/702Primary
Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages · CPC title
by agglomeration; by granulation, e.g. making powders · CPC title
Tabletting; Making food bars by compression of a dry powdered mixture · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9675649B2 cover?
- The invention provides formulations comprising isolated Disialyllacto-N-tetraose (DSLNT) or variants, isomers, analogs and derivatives thereof.
- Who is the assignee on this patent?
- Bode Lars, Univ California
- What technology area does this patent fall under?
- Primary CPC classification A61K31/702. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 13 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).